摘要
背景:阿尔茨海默病(AD)是老年人最常见的神经退行性痴呆,是全球老年人丧失能力和依赖他人的主要慢性疾病。临床上,AD的特征是进行性认知衰退,这干扰了执行日常生活活动的能力。手写和绘画是复杂的人类活动,需要复杂的认知,动觉和感知运动特征。 目的:比较AD患者与轻度认知障碍患者(MCI)和健康对照组之间手写和绘图的运动学特征。 方法:我们使用横截面和观察设计来评估使用计算机化系统的手写和绘图的运动和压力特征。 要求参与者复制一个句子,写一个指定句子和自己写的一个句子,复制二维三维图纸,并执行时钟绘图测试。 通过判别分析,我们探索了几种运动特征的价值,以便根据他们的认知功能程度对参与者进行分类。 结果:样本由52名参与者(23名AD,12名MCI和17名健康对照组成),平均年龄69.7岁(SD = 8.11)。 正确分类的程度在很大程度上取决于被分类群体的性质和具体任务,范围在63.5%到100%之间。 基于运动学测量的诊断准确性显示出更高的特异性值,用于区分正常和受损认知(MCI和AD),并且在区分受损认知水平(MCI与AD)时获得较高的灵敏度。 结论:写作和绘图程序只是代表了运动特征,而不是最终的结果,还需要有用和客观的的认知障碍患者临床评估补充。
关键词: 阿尔茨海默病,轻度认知障碍,运动学,手写,痴呆,记忆力丧失。
Current Alzheimer Research
Title:Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Volume: 14 Issue: 9
关键词: 阿尔茨海默病,轻度认知障碍,运动学,手写,痴呆,记忆力丧失。
摘要: Background: Alzheimer’s disease (AD) is the most common neurodegenerative dementia of old age, and the leading chronic disease contributor to disability and dependence among older people worldwide. Clinically, AD is characterized by a progressive cognitive decline that interferes with the ability to perform the activities of daily living. Handwriting and drawing are complex human activities that entail an intricate blend of cognitive, kinesthetic, and perceptual-motor features.
Objective: To compare the kinematic characteristics of handwriting and drawing between patients with AD, patients with mild cognitive impairment (MCI) and healthy controls. Methods: We used a cross-sectional and observational design to assess the kinematic and pressure features of handwriting and drawing using a computerized system. Participants were asked to copy one sentence, write a dictated sentence and an own sentence, copy two and-three dimensions drawings, and to execute the clock drawing test. By means of discriminant analyses, we explored the value of several kinematic features in order to classify participants depending on their degree of cognitive functioning. Results: The sample consisted of 52 participants (23 AD, 12 MCI, and 17 healthy controls) with a mean age of 69.7 years (SD=8.11). The degree of correct classification was largely dependent on the nature of the groups to be classified and the specific task, and ranged between 63.5% and 100%. Diagnostic accuracy based on kinematic measures showed higher specificity values for distinguishing between normal and impaired cognition (MCI and AD), and higher sensitivity was obtained when distinguishing between impaired cognition levels (MCI vs. AD). Conclusion: The kinematic features of writing and drawing procedures, rather than the final product, may be a useful and objective complement to the clinical assessment of patients with cognitive impairment.Export Options
About this article
Cite this article as:
Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls, Current Alzheimer Research 2017; 14 (9) . https://dx.doi.org/10.2174/1567205014666170309120708
DOI https://dx.doi.org/10.2174/1567205014666170309120708 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer’s Type
Current Neurovascular Research Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research Meet Our Associate Editor
Current Alzheimer Research Link Between Chronic Bacterial Inflammation and Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Anderson-Fabry Disease in Children
Current Pharmaceutical Design NAP Protects against Tau Hyperphosphorylation Through GSK3
Current Pharmaceutical Design Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Current Neuropharmacology Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis
Current Drug Targets - CNS & Neurological Disorders Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Neuropeptides in Alzheimer’s Disease: An Update
Current Alzheimer Research Subject Index To Volume 12
Current Pharmaceutical Design Mechanisms of Tau Self-Aggregation and Neurotoxicity
Current Alzheimer Research Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research